DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
| Brand name | QTERNMET XR |
|---|---|
| Active ingredient | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE |
| Strength | 5MG;1GM;EQ 2.5MG BASE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | May 2019 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 9616028*PED | May 2031 | — |
| 9616028 | November 2030 | product |
| 7919598*PED | June 2030 | — |
| 7919598 | December 2029 | substance |
| 8716251*PED | September 2028 | — |
| 8716251 | March 2028 | product |
| 8501698*PED | December 2027 | — |
| 8501698 | June 2027 | product |
| 6515117*PED | April 2026 | — |
| 6515117 | October 2025 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.